Acrivon posts ACR-368, ACR-2316 clinical update

Acrivon Therapeutics, Inc. reported that it hosted a corporate webcast and conference call on January 8, 2026, featuring a presentation by its leadership team and an interactive Q&A session.

Rhea-AI Filing Summary

Acrivon Therapeutics, Inc. reported that it hosted a corporate webcast and conference call on January 8, 2026, featuring a presentation by its leadership team and an interactive Q&A session. In connection with this event, the company posted a presentation on its investor relations website titled the January 8, 2026 Data Update. This presentation includes clinical data and program updates for the ACR-368 program as well as initial clinical data for ACR-2316.

The same January 8, 2026 Data Update has been furnished as Exhibit 99.1 to this report under a Regulation FD disclosure item, and is expressly not deemed filed for liability purposes under the Exchange Act unless later specifically incorporated by reference.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Acrivon Therapeutics (ACRV) disclose in this 8-K?

Acrivon disclosed that it hosted a corporate webcast and conference call and made available a January 8, 2026 Data Update presentation with ACR-368 and initial ACR-2316 clinical data.

Where can investors find Acrivon (ACRV)'s January 8, 2026 Data Update?

The January 8, 2026 Data Update presentation is posted in the Investors & Media section of Acrivon’s website at ir.acrivon.com and is also furnished as Exhibit 99.1.

Which Acrivon programs are covered in the January 8, 2026 Data Update?

The update includes ACR-368 clinical data and program updates, as well as initial clinical data for ACR-2316.

How is the January 8, 2026 Data Update treated for SEC purposes?

The information in Item 7.01, including Exhibit 99.1, is furnished under Regulation FD and is not deemed filed under Section 18 of the Exchange Act unless specifically incorporated by reference.

Which exhibit did Acrivon (ACRV) attach with this 8-K filing?

Acrivon attached Exhibit 99.1, titled “January 8, 2026 Data Update,” and identified the cover page interactive data file as Exhibit 104.

Did Acrivon announce any financial results in this 8-K?

No financial results are described; the report focuses on the company’s webcast and the accompanying January 8, 2026 Data Update presentation with clinical program information.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/08/2026 - 09:00 AM EST Learn about SEC filing dates

false000178117400017811742026-01-082026-01-08

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 08, 2026

Acrivon Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-41551	82-5125532
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
480 Arsenal Way Suite 100
Watertown, Massachusetts				02472
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (617) 207-8979

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		ACRV		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure

On January 8, 2026, Acrivon Therapeutics, Inc. (the “Company”) hosted a corporate webcast and conference call from approximately 8:30 a.m. to 9:00 a.m. ET. The agenda featured a presentation by the Company’s leadership team, followed by an interactive Q&A session. In connection with this event, the Company posted to the “Investors & Media” section of the Company’s website at ir.acrivon.com, the presentation used in the event (the “January 8, 2026 Data Update”). This update includes ACR-368 clinical data and program updates as well as initial ACR-2316 clinical data.

A copy of the January 8, 2026 Data Update is attached hereto as Exhibit 99.1 and is incorporated by reference into this Item 7.01 of this Current Report on Form 8-K.

The information in this Item 7.01, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

Exhibit Number		Description
99.1		January 8, 2026 Data Update
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Acrivon Therapeutics, Inc.
Date:	January 8, 2026	By:	/s/ Peter Blume-Jensen
			Name: Peter Blume-Jensen, M.D., Ph.D. Title: Chief Executive Officer and President